Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 4
2009 3
2010 1
2011 9
2012 5
2013 11
2014 7
2015 10
2016 14
2017 10
2018 12
2019 10
2020 6
2021 4
2022 8
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean The Type 1 diabetes trial net study group (244 results)?
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.
Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC; NIDDK Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Diabetes. 2022 Apr 1;71(4):610-623. doi: 10.2337/dbi20-0054. Diabetes. 2022. PMID: 35316839 Free PMC article. Review.
Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. ...Existing population screening programs rely on genetic or autoantibody screening, and th …
Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living wi …
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. ...RESULTS: A total of 76 participants (55 [72%] of whom were 18 years of age) underwent ra …
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells a …
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980. Sci Transl Med. 2021. PMID: 33658358 Free PMC article. Clinical Trial.
We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a previously reported randomized controlled trial of nondiabetic relatives at high risk for type 1 diabetes (T1D). In an ext …
We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a pre …
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC; Type 1 Diabetes TrialNet Study Group. Russell WE, et al. Diabetes Care. 2023 May 1;46(5):1005-1013. doi: 10.2337/dc22-2200. Diabetes Care. 2023. PMID: 36920087 Free PMC article. Clinical Trial.
OBJECTIVE: Previous studies showed that inhibiting lymphocyte costimulation reduces declining beta-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 dia …
OBJECTIVE: Previous studies showed that inhibiting lymphocyte costimulation reduces declining beta-cell function in individuals newly diagno …
The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.
Ismail HM, Cleves MA, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Ismail HM, et al. Diabetes Care. 2020 Nov;43(11):2668-2674. doi: 10.2337/dc20-0701. Epub 2020 Sep 8. Diabetes Care. 2020. PMID: 32900788 Free PMC article.
OBJECTIVE: Glucose response curves (GRCs) during oral glucose tolerance tests (OGTTs) are predictive of type 1 diabetes. We performed a longitudinal analysis in pancreatic autoantibody-positive individuals to assess 1) characteristic GRC changes during …
OBJECTIVE: Glucose response curves (GRCs) during oral glucose tolerance tests (OGTTs) are predictive of type 1 diabetes …
Hydroxychloroquine in Stage 1 Type 1 Diabetes.
Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC; Type 1 Diabetes TrialNet Study Group. Libman I, et al. Diabetes Care. 2023 Nov 1;46(11):2035-2043. doi: 10.2337/dc23-1096. Diabetes Care. 2023. PMID: 37708415
OBJECTIVE: Innate immune responses may be involved in the earliest phases of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: To test whether blocking innate immaune cells modulated progression of the disease, we randomly assigned 273 individuals with stag …
OBJECTIVE: Innate immune responses may be involved in the earliest phases of type 1 diabetes (T1D). RESEARCH DESIGN AND …
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.
Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. Mahon JL, et al. Pediatr Diabetes. 2009 Apr;10(2):97-104. doi: 10.1111/j.1399-5448.2008.00464.x. Epub 2008 Sep 24. Pediatr Diabetes. 2009. PMID: 18823409 Clinical Trial.
OBJECTIVES: TrialNet's goal to test preventions for type 1 diabetes has created an opportunity to gain new insights into the natural history of pre-type 1 diabetes. The TrialNet Natural History Study (NHS) will assess …
OBJECTIVES: TrialNet's goal to test preventions for type 1 diabetes has created an opportunity to gain new insig …
A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes.
Girdhar K, Huang Q, Chow IT, Vatanen T, Brady C, Raisingani A, Autissier P, Atkinson MA, Kwok WW, Kahn CR, Altindis E. Girdhar K, et al. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2120028119. doi: 10.1073/pnas.2120028119. Epub 2022 Jul 25. Proc Natl Acad Sci U S A. 2022. PMID: 35878027 Free PMC article.
Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta-cells. ...Finally, analysis of human children gut microbiome data from a longitudinal DIABIMMUNE study revealed that seroconversion rates (i.e., the prop …
Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta-cells. ...Finally, a …
Clinical and experimental treatment of type 1 diabetes.
Long SA, Buckner JH. Long SA, et al. Clin Exp Immunol. 2022 Dec 15;210(2):105-113. doi: 10.1093/cei/uxac077. Clin Exp Immunol. 2022. PMID: 35980300 Free PMC article. Review.
Type 1 diabetes (T1D) is an autoimmune disease resulting in the destruction of the insulin-producing pancreatic beta cells. ...
Type 1 diabetes (T1D) is an autoimmune disease resulting in the destruction of the insulin-producing pancreatic beta ce …
HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.
Felton JL, Cuthbertson D, Warnock M, Lohano K, Meah F, Wentworth JM, Sosenko J, Evans-Molina C; Type 1 Diabetes TrialNet Study Group. Felton JL, et al. Diabetologia. 2022 Jan;65(1):88-100. doi: 10.1007/s00125-021-05573-6. Epub 2021 Oct 12. Diabetologia. 2022. PMID: 34642772 Free PMC article.
The utility of HOMA2-B in association with type 1 diabetes progression has not been tested. METHODS: Baseline HOMA2-B values from single-Aab+ (n = 2652; mean age, 21.1 14.0 years) and multiple-Aab+ (n = 3794; mean age, 14.5 11.2 years) individuals enro …
The utility of HOMA2-B in association with type 1 diabetes progression has not been tested. METHODS: Baseline HOMA2-B v …
108 results